South Korea · Delayed Price · Currency is KRW J2KBIO Statistics
Total Valuation
J2KBIO has a market cap or net worth of KRW 44.67 billion. The enterprise value is 33.11 billion.
| Market Cap | 44.67B |
| Enterprise Value | 33.11B |
Important Dates
The next estimated earnings date is Tuesday, May 12, 2026.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
J2KBIO has 5.85 million shares outstanding. The number of shares has increased by 5.36% in one year.
| Current Share Class | 5.85M |
| Shares Outstanding | 5.85M |
| Shares Change (YoY) | +5.36% |
| Shares Change (QoQ) | -0.13% |
| Owned by Insiders (%) | 62.03% |
| Owned by Institutions (%) | n/a |
| Float | 2.22M |
Valuation Ratios
The trailing PE ratio is 16.64.
| PE Ratio | 16.64 |
| Forward PE | n/a |
| PS Ratio | 1.36 |
| PB Ratio | 1.32 |
| P/TBV Ratio | 1.34 |
| P/FCF Ratio | 36.90 |
| P/OCF Ratio | 21.50 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.49, with an EV/FCF ratio of 27.35.
| EV / Earnings | 12.39 |
| EV / Sales | 1.00 |
| EV / EBITDA | 7.49 |
| EV / EBIT | 11.34 |
| EV / FCF | 27.35 |
Financial Position
The company has a current ratio of 7.09, with a Debt / Equity ratio of 0.03.
| Current Ratio | 7.09 |
| Quick Ratio | 5.86 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.26 |
| Debt / FCF | 0.94 |
| Interest Coverage | 62.61 |
Financial Efficiency
Return on equity (ROE) is 8.21% and return on invested capital (ROIC) is 11.40%.
| Return on Equity (ROE) | 8.21% |
| Return on Assets (ROA) | 4.93% |
| Return on Invested Capital (ROIC) | 11.40% |
| Return on Capital Employed (ROCE) | 8.35% |
| Weighted Average Cost of Capital (WACC) | 5.54% |
| Revenue Per Employee | 610.49M |
| Profits Per Employee | 49.50M |
| Employee Count | 54 |
| Asset Turnover | 0.89 |
| Inventory Turnover | 6.70 |
Taxes
In the past 12 months, J2KBIO has paid 369.49 million in taxes.
| Income Tax | 369.49M |
| Effective Tax Rate | 12.14% |
Stock Price Statistics
The stock price has decreased by -38.59% in the last 52 weeks. The beta is 0.24, so J2KBIO's price volatility has been lower than the market average.
| Beta (5Y) | 0.24 |
| 52-Week Price Change | -38.59% |
| 50-Day Moving Average | 8,007.40 |
| 200-Day Moving Average | 8,947.10 |
| Relative Strength Index (RSI) | 46.78 |
| Average Volume (20 Days) | 9,933 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, J2KBIO had revenue of KRW 32.97 billion and earned 2.67 billion in profits. Earnings per share was 459.00.
| Revenue | 32.97B |
| Gross Profit | 12.98B |
| Operating Income | 2.92B |
| Pretax Income | 3.04B |
| Net Income | 2.67B |
| EBITDA | 4.42B |
| EBIT | 2.92B |
| Earnings Per Share (EPS) | 459.00 |
Balance Sheet
The company has 12.70 billion in cash and 1.13 billion in debt, with a net cash position of 11.57 billion or 1,977.96 per share.
| Cash & Cash Equivalents | 12.70B |
| Total Debt | 1.13B |
| Net Cash | 11.57B |
| Net Cash Per Share | 1,977.96 |
| Equity (Book Value) | 33.77B |
| Book Value Per Share | 5,783.06 |
| Working Capital | 18.85B |
Cash Flow
In the last 12 months, operating cash flow was 2.08 billion and capital expenditures -866.78 million, giving a free cash flow of 1.21 billion.
| Operating Cash Flow | 2.08B |
| Capital Expenditures | -866.78M |
| Depreciation & Amortization | 1.50B |
| Net Borrowing | -270.53M |
| Free Cash Flow | 1.21B |
| FCF Per Share | 207.05 |
Margins
Gross margin is 39.37%, with operating and profit margins of 8.86% and 8.11%.
| Gross Margin | 39.37% |
| Operating Margin | 8.86% |
| Pretax Margin | 9.23% |
| Profit Margin | 8.11% |
| EBITDA Margin | 13.41% |
| EBIT Margin | 8.86% |
| FCF Margin | 3.67% |
Dividends & Yields
This stock pays an annual dividend of 250.00, which amounts to a dividend yield of 3.27%.
| Dividend Per Share | 250.00 |
| Dividend Yield | 3.27% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 2 |
| Payout Ratio | 44.75% |
| Buyback Yield | -5.36% |
| Shareholder Yield | -2.09% |
| Earnings Yield | 5.98% |
| FCF Yield | 2.71% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
J2KBIO has an Altman Z-Score of 10.35 and a Piotroski F-Score of 5.
| Altman Z-Score | 10.35 |
| Piotroski F-Score | 5 |